Compare Kroger Co (KR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs ResMed Inc. — how do they compare? Kroger Co trades at $60.87 (market cap $36.27B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: Kroger Co and ResMed Inc. are close in size by market cap, and Kroger Co pays the higher dividend (2.54%). Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and ResMed Inc. for 51 Days on average.
| KR | RMD | |
|---|---|---|
Market Cap | $36.27B | $31.89B |
Volume | 8,301,523 | 618,314 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $277.88 |
52-Week Low | $55.53 | $182.82 |
Typical Hold Time | 108 Days | 51 Days |
Enterprise Value | $57.69B | $31.24B |
Dividend Yield | 2.54% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.64, up 4.03% today, with a bullish technical signal supported by moving averages. The stock shows mixed fundamentals with a low P/S ratio of 0.26 but elevated P/E of 33.19, while recent earnings beat expectations in two of the last three quarters. Analyst consensus is moderately bullish with a $70.62 price target, representing 14.6% upside potential from current levels.
Kroger offers value through its low valuation multiples and consistent dividends, but faces headwinds from competitive pressures and integration risks from pending acquisitions. The company's digital growth initiatives and retail media expansion provide growth catalysts, though margin compression remains a concern amid rising costs and softer sales guidance for fiscal 2026.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
